31st March, 2011 :
(3)
Payments
Amount
(4)
(5)
[An
41,60
8,000
12,000
2,000
Prepara
(28) Th
(26). The following is the Receipts and Payments Account of the Young Club for the year ended
Receipts and Payments Account
(for the year ended 31st March, 2011)
(i) There are 450 members each paying an annual subscription of 7 100. * 900 being in artean
(iii) At 31st March, 2011; the rates were prepaid to the following 30th June, the yearly charge
being * 12,000. A quarter's charge for telephone is outstanding, the amount accrued
SBPD Publications Financial Accounting
Receipts
Amount
7
1-4-2010
Balance b/d
Subscriptions :
2011-12
2010-11
42,200
2009-10
800
Sports Meeting Profit
Dividends on Investments
The following additional information are available :
of 2009-10 at the beginning at 2010-11.
(ii) Stock of Stationery at 31st March, 2010 was * 1,000; at 31st March, 2011 F 1,800.
being * 700. Expenses accruing at 31st March, 2010 7 1,400.
(iv) At 31st March, 2010, the building stood in the books at * 2,00,000 and it is required to
cch, 2010 were * 4,00,000.
write off depreciation @ 5% p.a. Investments at 31st
You are required to prepare an Income and Expenditure Account for the year ended 314
March, 2011 and a Balance Sheet at the date.
31-3-2011
20,500 Salaries
F
Stationery
1,600
Rates
Telephone
44,600 Investments
31,000 (In 725,000, 4% stock at par)
20,000 Sundry Expenses
Balance dd
1,16,100
25,000
18,500
9,000
T
T
T
1,16,100
T
1
Answers
Answer:
WHO announced that the hydroxychloroquine (HCQ) arm of the Solidarity Trial to find an effective COVID-19 treatment was being stopped.
The trial's Executive Group and principal investigators made the decision based on evidence from the Solidarity trial, UK's Recovery trial and a Cochrane review of other evidence on hydroxychloroquine.
Data from Solidarity (including the French Discovery trial data) and the recently announced results from the UK's Recovery trial both showed that hydroxychloroquine does not result in the reduction of mortality of hospitalised COVID-19 patients, when compared with standard of care.
Investigators will not randomize further patients to hydroxychloroquine in the Solidarity trial. Patients who have already started hydroxychloroquine but who have not yet finished their course in the trial may complete their course or stop at the discretion of the supervising physician.
Explanation: